Froedtert and the Medical College of Wisconsin Froedtert Hospital in Milwaukee became the next clinical site for InVivo Therapeutics' spinal cord injury treatment investigational device exemption clinical trial.
Here are five key updates:
1. Froedtert Hospital has the only Level 1 trauma center in eastern Wisconsin and receives spinal cord injury patients from Wisconsin, northern Illinois and northern Michigan.
2. The principal investigator at the site is Director of the Spinal Cord Injury Center and Spine Surgery Fellowship at Froedtert Hospital Shekar Kurpad, MD.
3. This is the first clinical study of InVivo's Neuro-Spinal Scaffold — FDA-approved for the IDE study intended to provide preliminary safety and efficacy data.
4. The second patient was enrolled in the trial on Jan. 22 at the Carolinas Medical Center in Charlotte, N.C., location.
5. There are now seven sites prepared to participate in the clinical trail.
"We're very pleased to have Dr. Kurpad and MCW join our pilot study," said InVivo CEO Mark Perrin. "Dr. Kurpad has extensive experience in spinal cord injury and was the recipient of the prestigious Van Wagenen fellowship from the American Association of Neurological Surgeons."